IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer

被引：487

作者：

Neurath, Markus F. ^{[1
]}

Finotto, Susetta ^{[1
]}

机构：

[1] Univ Erlangen Nurnberg, Med Clin 1, D-91054 Erlangen, Germany

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2011年 / 22卷 / 02期

关键词：

IL-6; Cytokines; TH17; cells; T cell differentiation; Regulatory and effector T cells; Inflammatory bowel disease; Asthma; Rheumatoid arthritis; Cancer; CHRONIC INTESTINAL INFLAMMATION; CELL-MEDIATED COLITIS; NECROSIS-FACTOR-ALPHA; CD4(+) T-CELLS; INTERLEUKIN-6; IL-6; BOWEL-DISEASE; TGF-BETA; IL-6-DEFICIENT MICE; RHEUMATOID-ARTHRITIS; CUTTING EDGE;

D O I：

10.1016/j.cytogfr.2011.02.003

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

IL-6 activates various cell types carrying the membrane bound IL-6R (classical IL-6 signaling) as well as IL-6R(-) gp130(+) cells via the soluble IL-6R (IL-6 trans-signaling). IL-6 signaling plays a pivotal role in controlling the differentiation and activation of T lymphocytes by inducing the Jak/STAT-3 and the Ras/Erk/C/EBP pathways. In particular, IL-6 modulates the resistance of T cells against apoptosis, induces activation of T helper cells and controls the balance between regulatory T cells and Th17 cells. Importantly, recent findings suggest that blockade of IL-6 signaling is effective in treating experimental models of autoimmune and chronic inflammatory diseases such as inflammatory bowel diseases, diabetes, multiple sclerosis, asthma and rheumatoid arthritis as well as models of inflammation-associated cancer. Thus, anti-IL-6/anti-IL-6R strategies emerge as promising novel approaches for therapy of inflammatory diseases in humans. In this review article, we discuss the latest findings on the role of IL-6 in experimental models of autoimmunity and cancer, as well as clinical perspectives. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：83 / 89

页数：7

共 113 条

[11] Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].

Chen, WJ ;

Jin, WW ;

Hardegen, N ;

Lei, KJ ;

Li, L ;

Marinos, N ;

McGrady, G ;

Wahl, SM .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886

[12] AIRWAY EPITHELIAL-CELL EXPRESSION OF INTERLEUKIN-6 IN TRANSGENIC MICE - UNCOUPLING OF AIRWAY INFLAMMATION AND BRONCHIAL HYPERREACTIVITY [J].

DICOSMO, BF ;

GEBA, GP ;

PICARELLA, D ;

ELIAS, JA ;

RANKIN, JA ;

STRIPP, BR ;

WHITSETT, JA ;

FLAVELL, RA .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (05) :2028-2035

[13] Lower Airway Disease in Asthmatics with and without Rhinitis [J].

Dixon, Anne E. ;

Raymond, Danielle M. ;

Suratt, Benjamin T. ;

Bourassa, Lorraine M. ;

Irvin, Charles G. .

LUNG, 2008, 186 (06) :361-368

[14] Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children [J].

Dogan, Yasar ;

Akarsu, Saadet ;

Ustundag, Bilal ;

Yilmaz, Erdal ;

Gurgoze, Metin Kaya .

MEDIATORS OF INFLAMMATION, 2006, 2006

[15] The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo [J].

Doganci, A ;

Eigenbrod, T ;

Krug, N ;

De Sanctis, GT ;

Hausding, M ;

Erpenbeck, VJ ;

Haddad, EB ;

Schmitt, E ;

Bopp, T ;

Kallen, KJ ;

Herz, U ;

Schmitt, S ;

Luft, C ;

Hecht, O ;

Hohlfeld, JM ;

Ito, H ;

Nishimoto, N ;

Yoshizaki, K ;

Kishimoto, T ;

Rose-John, S ;

Renz, H ;

Neurath, MF ;

Galle, PR ;

Finotto, S .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :313-325

[16] Pathological role of IL-6 in the experimental allergic bronchial asthma in mice [J].

Doganci, A ;

Sauer, K ;

Karwot, R ;

Finotto, S .

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2005, 28 (03) :257-269

[17] Cutting edge:: Trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+ CD25- T cells [J].

Dominitzki, Sabine ;

Fantini, Massimo C. ;

Neufert, Clemens ;

Nikolaev, Alexei ;

Galle, Peter R. ;

Scheller, Juergen ;

Monteleone, Giovanni ;

Rose-John, Stefan ;

Neurath, Markus F. ;

Becker, Christoph .

JOURNAL OF IMMUNOLOGY, 2007, 179 (04) :2041-2045

[18] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].

Emery, P. ;

Keystone, E. ;

Tony, H. P. ;

Cantagrel, A. ;

van Vollenhoven, R. ;

Sanchez, A. ;

Alecock, E. ;

Lee, J. ;

Kremer, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523

[19]

Eugster HP, 2001, EUR J IMMUNOL, V31, P2302, DOI 10.1002/1521-4141(200108)31:8<2302::AID-IMMU2302>3.0.CO

[20]

2-#

← 1 2 3 4 5 6 7 8 9 10 →